A Phase 2 interventional study of Irinotecan + Carboplatin and irinotecan + Carboplatin + erbitux in Metastatic Breast Cancer, sponsored by US Oncology Research. Active, not recruiting at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing irinotecan in Breast Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Irinotecan · Breast Neoplasms.
Among the 24 studies testing irinotecan in Breast Neoplasms, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2005, is one of 15 in phase 2, and was the 9th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 24 studies testing irinotecan in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
By country, each count listing its studies:
Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 1
First in 1998; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 38 across the 23 interventional studies. Of the 17 that completed or were terminated, 4 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
11 studies in Breast Neoplasms by Sarah Cannon Research Institute: none open now, 2 under way, none of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2005, is one of 8 in phase 2, and was the 1st registered.
Sarah Cannon Research Institute’s Breast Neoplasms studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing irinotecan in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sarah Cannon Research Institute’s 11 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female patients will be eligible for inclusion in this study if they meet all of the following criteria:
NOTE: Ascites, pleural effusion, and bone metastases are not considered measurable.
NOTE: Previously irradiated lesions will not be evaluable; however, these patients will still be eligible. Patients must have at least 1 at baseline.
NOTE: Availability of samples should be confirmed prior to randomization (at latest, prior to first dose).
EXCLUSION CRITERIA:
NOTE: If patient was receiving prior weekly or daily chemotherapy, he/she may begin study therapy 2 weeks after stopping prior therapy provided all toxicities have resolved; peripheral neuropathy must be less than Grade I as per exclusion criterion #8 above.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)
Drug: Irinotecan + Carboplatin
irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)
Drug: irinotecan + Carboplatin + erbitux
Drug pages: Irinotecan · Carboplatin
irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
Drug pages: Irinotecan · Carboplatin · Cetuximab
irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
Objective Response Rates (ORR)
To determine the objective response rates (CR + PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Time frame: 2 years
Duration of Response
The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
Time frame: From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 60 months.
Median Time of Progression-free Survival (PFS)
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
Time frame: 2 years
Median Overall Survival (OS)
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
Time frame: 2 years
| Milestone | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| Started | 75 | 79 |
| Completed | 51 | 60 |
| Not completed | 24 | 19 |
| Withdrew: Adverse event | 11 | 10 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Investigator request | 4 | 3 |
| Withdrew: Patient request | 5 | 3 |
| Withdrew: Other | 3 | 2 |
To determine the objective response rates (CR + PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
| Percentage of Participants | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| Objective Response Rates (ORR) | 36.4 (24.9 to 49.1) | 36.6 (25.5 to 48.9) |
The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
| months | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| Duration of Response | 5.4 (2.0 to 34.3) | 6.0 (1.4 to 41.3) |
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.
| months | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| Median Time of Progression-free Survival (PFS) | 4.4 (3.2 to 5.8) | 4.6 (3.5 to 5.5) |
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
| months | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| Median Overall Survival (OS) | 12.5 (10.6 to 17.1) | 14.6 (10.4 to 16.9) |
Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Irinotecan+Carboplatin | 1/75 (1.3%) | 14/75 (18.7%) | 73/75 (97.3%) |
| Irinotecan+Carboplatin+Cetuximab | 0/79 (0%) | 18/79 (22.8%) | 79/79 (100%) |
| Event | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| DIARRHEAGastrointestinal disorders | 5/75 | 9/79 |
| DEHYDRATIONGastrointestinal disorders | 8/75 | 6/79 |
| NEUTROPENIABlood and lymphatic system disorders | 3/75 | 2/79 |
| WEAKNESS GENERALIZEDGeneral disorders | 2/75 | 0/79 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/75 | 2/79 |
| HYPOMAGNESEMIAMetabolism and nutrition disorders | 0/75 | 2/79 |
| NAUSEAGastrointestinal disorders | 1/75 | 2/79 |
| SEPSISInfections and infestations | 0/75 | 2/79 |
| ALLERGIC REACTIONImmune system disorders | 1/75 | 0/79 |
| ANAPHYLAXISImmune system disorders | 1/75 | 0/79 |
| Event | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab |
|---|---|---|
| DIARRHEAGastrointestinal disorders | 50/75 | 58/79 |
| NAUSEAGastrointestinal disorders | 55/75 | 47/79 |
| NEUTROPENIABlood and lymphatic system disorders | 53/75 | 56/79 |
| RASHSkin and subcutaneous tissue disorders | 14/75 | 56/79 |
| FATIGUEGeneral disorders | 45/75 | 51/79 |
| ANEMIABlood and lymphatic system disorders | 47/75 | 40/79 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 39/75 | 32/79 |
| VOMITINGGastrointestinal disorders | 30/75 | 34/79 |
| LEUCOPENIABlood and lymphatic system disorders | 29/75 | 32/79 |
| ALOPECIASkin and subcutaneous tissue disorders | 20/75 | 27/79 |
ITT population
| Age, Continuous(years) | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab | Total |
|---|---|---|---|
| Mean | 53.7 ± 11.4 | 54.9 ± 10.7 | 54.3 ± 11.0 |
| Sex: Female, Male(Participants) | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab | Total |
|---|---|---|---|
| Female | 75 | 79 | 154 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab | Total |
|---|---|---|---|
| Caucasian | 59 | 69 | 128 |
| Black | 14 | 8 | 22 |
| Hispanic | 2 | 2 | 4 |
| Region of Enrollment(participants) | Irinotecan+Carboplatin | Irinotecan+Carboplatin+Cetuximab | Total |
|---|---|---|---|
| United States | 75 | 79 | 154 |
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jul 2005 (actual). Primary completion is estimated for Dec 2025, 245 months after the start.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 245 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Irinotecan · Carboplatin · Cetuximab